{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Yebyo HG"],"funding":["Intramural NIH HHS","NCATS NIH HHS","NIDA NIH HHS","NIA NIH HHS","NCRR NIH HHS","NIAID NIH HHS","NHLBI NIH HHS","NIMH NIH HHS","NIAAA NIH HHS","Swiss National Science Foundation","NEI NIH HHS","NIMHD NIH HHS","NCI NIH HHS"],"pagination":["e001132"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12090529"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["4(1)"],"pubmed_abstract":["<h4>Objective</h4>To evaluate the effectiveness and benefit-harm balance of various statins for the primary prevention of cardiovascular disease in people with HIV.<h4>Design</h4>Target trial and modelling study.<h4>Setting</h4>North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), 1995 to 2019. NA-ACCORD integrates individual level data from >20 HIV cohorts across the US and Canada from people with HIV who have successfully linked into care.<h4>Participants</h4>157 699 people with HIV enrolled in one of the cohorts of NA-ACCORD. 54 165 eligible individuals, aged 40-75 years, were enrolled in the target trial.<h4>Main outcome measures</h4>The primary outcomes for the target trial were the 10 year effects of statins on cardiovascular disease events (fatal and non-fatal"],"journal":["BMJ medicine"],"pubmed_title":["Statins for primary prevention of cardiovascular events in people with HIV: target trial and modelling study."],"pmcid":["PMC12090529"],"funding_grant_id":["K01 AI131895","K24 DA000432","U01 AI038858","U01 HL146205","U01 HL146204","KL2 TR000421","U01 AI038855","U01 HL146203","U01 HL146208","R01 DA011602","U01 AI068636","R01 AA016893","U01 HL146242","U01 HL146241","U01 AA020790","U01 HL146240","N02 CP055504","U01 HL146202","U01 HL146245","U01 HL146201","UL1 TR000083","U01 AI068634","K23 EY013707","U10 EY008067","P30 AI027767","P30 AI027763","P30 AI036219","F31 AI124794","UL1 TR000004","U24 AA020794","194504","U01 HL146194","U01 HL146193","U01 HL146192","P30 AI050410","K01 AI093197","U10 EY008057","P30 AI027757","U01 AA013566","P30 AI110527","F31 DA037788","U10 EY008052","G12 MD007583","UL1 RR024131","P30 AI094189","R24 AI067039","U01 DA036935","K24 AI065298","R01 AG053100","N01 CP001004","P30 MH062246","R01 DA012568","P30 AI050409","U01 HL146333","U01 AI069918","U54 MD007587","Z01 CP010176","U01 AI069432","K24 AI118591","U01 AI069434"],"pubmed_authors":["Guenthard HF","Rehfuess EA","Senn O","Loutfy M","Sterling TR","Yebyo HG","Serra N","Haile SR","Langselius O","Napravnik S","Thorne JE","Marconi VC","Lucas GM","Burkholder GA","Althoff KN","Karris M","Coburn SB","Lang R","Puhan MA","Silverberg MJ","Colasanti JA"],"additional_accession":[]},"is_claimable":false,"name":"Statins for primary prevention of cardiovascular events in people with HIV: target trial and modelling study.","description":"<h4>Objective</h4>To evaluate the effectiveness and benefit-harm balance of various statins for the primary prevention of cardiovascular disease in people with HIV.<h4>Design</h4>Target trial and modelling study.<h4>Setting</h4>North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), 1995 to 2019. NA-ACCORD integrates individual level data from >20 HIV cohorts across the US and Canada from people with HIV who have successfully linked into care.<h4>Participants</h4>157 699 people with HIV enrolled in one of the cohorts of NA-ACCORD. 54 165 eligible individuals, aged 40-75 years, were enrolled in the target trial.<h4>Main outcome measures</h4>The primary outcomes for the target trial were the 10 year effects of statins on cardiovascular disease events (fatal and non-fatal","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025","modification":"2026-03-27T16:44:41.874Z","creation":"2025-08-31T03:04:48.215Z"},"accession":"S-EPMC12090529","cross_references":{"pubmed":["40395649"],"doi":["10.1136/bmjmed-2024-001132"]}}